Correction pubs.acs.org/bc
Correction to Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer Christos Liolios,* Martin Schaf̈ er, Uwe Haberkorn, Matthias Eder,* and Klaus Kopka Bioconjugate Chemistry 2016, 27 (3), 737−751. DOI: 10.1021/acs.bioconjchem.5b00687 1. The corrected Figure 5a is included here. The top image corresponds to the sagittal view (instead of axial), while the bottom image to the axial (instead of sagittal). 2. In the Results section, page 738, first paragraph, 12th line, the abbreviation number for GRPm is 12 rather than 16.
Figure 5. Whole-body μPET (sagittal, coronal, and axial, from top to bottom) images of athymic male nu/nu mice bearing LNCaP tumor xenografts for 68 Ga-labeled HE0 (16) (a) and HE2 (19) (b). T: tumor; K: kidneys; B: bladder (as indicated with arrows). (c) Representative time−activity curves taken from the dynamic PET measurements (0−60 min p.i.) expressed as SUVmean (standardized uptake values) for 68Ga-labeled HE0 (c) and HE2 (d). SUV time−activity curves for the organs of interest are represented as follows: M: muscle; L: liver; H: heart; T: tumor; K: kidneys; B: bladder.
© XXXX American Chemical Society
A
DOI: 10.1021/acs.bioconjchem.6b00311 Bioconjugate Chem. XXXX, XXX, XXX−XXX
